Skip to main content
How does TAFINLAR + MEKINIST treat NSCLC?

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic NSCLC), and that has a certain type of abnormal “BRAF V600E” gene. TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type BRAF NSCLC.

If you have the BRAF V600E mutation, TAFINLAR + MEKINIST is a targeted therapy for your specific type of metastatic NSCLC

Could TAFINLAR + MEKINIST be right for you?

Your health care provider will perform a biomarker test to make sure that TAFINLAR, in combination with MEKINIST, is right for you.

It is not known if TAFINLAR with MEKINIST is safe and effective in children younger than 6 years of age.

TAFINLAR + MEKINIST is a proven choice for patients with BRAF V600E metastatic NSCLC.

Before starting NSCLC treatment
Health care dialogue icon

It is important to keep an open dialogue with your health care provider. Tell your health care provider about all of your medical conditions, including if you:

  • Have had bleeding problems or blood clots

  • Have stomach problems

  • Have inflammation of the colon

  • Have heart problems

  • Have eye problems

  • Have lung or breathing problems

  • Have high blood pressure (hypertension)

  • Have liver or kidney problems

  • Have diabetes

  • Plan to have surgery, dental, or other medical procedures

  • Have a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme

  • Are pregnant or plan to become pregnant. TAFINLAR and MEKINIST can harm your unborn baby

  • Are breastfeeding or plan to breastfeed. It is not known if TAFINLAR and/or MEKINIST passes into your breast milk

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES